Multiple Myeloma Clinical Trial

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM

Summary

A total of 207 subjects will be randomized into the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

View Full Description

Full Description

Part 1: This lead-in period, designed to ascertain the dose of BL-8040, enrolled a total of 12 subjects to an open labeled treatment to assess the efficacy, safety, PK and PD parameters of treatment with G-CSF 10 µg/kg/day and BL-8040 1.25 mg/kg, per study protocol to goal collection of ≥ 6 × 10^6 CD34+ cells/kg.
Part 2: Following the successful completion of Part 1, a total of 122 subjects were randomized into Part 2 of the study which employed a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed Multiple Myeloma prior to enrolment and randomization.
At least 1 week (7 days) from last induction cycle of combination/multi-agent cyto-reductive chemotherapy (e.g., KRD [carfilzomib, lenalidomide, dexamethasone] or VRD (e.g., bortezomib, lenalidomide, dexamethasone) or last single agent chemotherapy (e.g., lenalidomide, pomalidomide, bortezomib, dexamethasone, etc.) prior to the first dose of G-CSF for mobilization.
Eligible for autologous hematopoietic stem cell transplantation according to the Investigator's discretion.
The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

Adequate organ function at screening as defined as below:

Hematology:

White blood cell counts more than 2.5 x 109/L
Absolute neutrophil count more than 1.5 x 109/L

Platelet count more than 100 x109/L Renal Function:

• GFR value of ≥15 mL/min/1.732 calculated by MDRD equation

Hepatic function:

ALT and/or AST ≤ 2.5 x ULN
Total Bilirubin ≤ 2.0 x ULN unless the subject has Gilbert disease

Coagulation test:

INR or PT: ≤1.5xULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
aPTT: ≤1.5xULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Male subjects must agree to use an adequate method of contraception starting with the first day of G-CSF administration through 30 days after the last dose of study drug.
Patients must have a signed study informed consent prior to entering the study.

Exclusion Criteria:

Previous history of autologous or allogeneic-HCT.
Failed previous HSC collections or collection attempts.

Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:

Dexamethasone: 7 days;
Thalidomide: 7 days;
Lenalidomide: 7 days;
Pamolidomide: 7 days;
Bortezomib: 7 days;
Carfilzomib: 7 days;
G-CSF: 14 days;
GM-CSF or Neulasta®: 21 days;
Erythropoietin or erythrocyte stimulating agents: 30 days;
Eltrombopag, romiplostim or platelet stimulating agents: 30 days;
Carmustine (BCNU): 42 days/6 weeks;
Daratumumab: 28 days;
Ixazomib: 7 days.
Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
Received >8 cycles of alkylating agent combinations.
Received >6 cycles of melphalan.
Received prior treatment with radioimmunotherapy (e.g., radionuclides, holmium).
Received prior treatment wiht venetoclax.
Plans to receive maintenance treatment within 60 days post-engraftment (e.g., lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.)
Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
Known active CNS metastases or carcinomatous meningitis.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
Has an active infection requiring systemic therapy or uncontrolled infection.
Has a known additional malignancy that is progressing or requires active treatment.
Has an underlying medical condition that would preclude study participation.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
O2 saturation < 92% (on room air).
Personal history or family history of Long QT Syndrome or Torsade de Pointes.
History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Angina Pectoris Class >2 or NYHA Heart Failure >2.
ECG in screening showing QTcF > 470 msec, and/or PR > 280 msec,.
Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is notin the best interest of the subject to participate, in the opinion of the treating investigator.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of study drug.
Has a known history of HIV (HIV 1/2 antibodies)
Has known active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is detected).
Untreated or unsuccessfully treated Hepatitis B or C.

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

180

Study ID:

NCT03246529

Recruitment Status:

Active, not recruiting

Sponsor:

BioLineRx, Ltd.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 18 Locations for this study

See Locations Near You

UCLA Medical Center
Los Angeles California, 16781, United States
University of Florida
Gainesville Florida, 10027, United States
University of Miami
Miami Florida, 33136, United States
Loyola University Medical Center
Chicago Illinois, 60611, United States
University of Maryland
Baltimore Maryland, 21201, United States
Mayo Clinic
Rochester Minnesota, 55902, United States
The Washington University School of Medicine
Saint Louis Missouri, 63110, United States
University of Cincinnati
Cincinnati Ohio, 45221, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Huntsman Cancer Institute in University of Utah
Salt Lake City Utah, 84112, United States
University of Koln
Köln Koln, 50923, Germany
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases
Budapest , 1097, Hungary
University of Debrecen
Debrecen , 4032, Hungary
Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele
Catania , 95124, Italy
Presidio Ospedaliero Morelli Viale Europa
Reggio Calabria , 89133, Italy
Hospital de La Santa Creu I Sant Pau
Barcelona , 08041, Spain
Hospital University Ramon y Cajal
Madrid , 13525, Spain
Hospital Universitario 12 de Octubre
Madrid , 28041, Spain

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

180

Study ID:

NCT03246529

Recruitment Status:

Active, not recruiting

Sponsor:


BioLineRx, Ltd.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.